

COVID-19 Guidance for High Level Disinfection of Flexible Endoscopes

March 2020

Cantel continues to monitor updates from the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which causes the disease now called Coronavirus Disease 2019 (COVID-19). On January 30, 2020 the WHO officially declared the outbreak a Public Health Emergency of International Concern (PHEIC).

Due to the novel nature of the virus, no official methods exist to test the efficacy of a disinfectant against the SARS-CoV-2 pathogen, as these procedures take a significant amount of time to develop, validate, and standardize. In the meantime, disinfectant manufacturers, care givers, environmental health and safety workers, and patients must rely on updates from groups like the CDC and WHO to ensure they are executing the most relevant procedures to protect against the spread of this highly infectious agent.

In the absence of a validated test, Cantel has taken steps to understand SARS-CoV-2 and the efficacy of our high-level disinfectants (HLDs) and sterilants against it. Previous confirmatory testing performed by a third-party laboratory has verified that Cantel's 5% peracetic acid concentrates¹ demonstrate a complete inactivation of the 229E human coronavirus strain, in 5 minutes at room temperature.² Additionally, these HLD/sterilant products carry virucidal efficacy claims against enveloped³ and more challenging, non-enveloped viruses⁴ such as poliovirus type 2⁵ and many other more 'robust' pathogens.⁵

When performing disinfection steps using HLDs and sterilants from Cantel, you can be assured that if used in accordance with their instructions for use and for their indicated purposes, these products have validated efficacy against certain challenging pathogens and will provide high level efficacy in accordance with the products' published specifications and labeling information.⁶



Kristopher Murphy, PhD
Director of Chemistry – R&D



April Doering
Sr Director Microbiology & Sterilization



- 1) MINNCARE™ Cold Sterilant, RAPICIDE™ PA, RAPICIDE™ PA RTU, REVOX™ PA, ADASPOR™ HLD, ADASPOR™ HLD RTU, ADASPOR™ Plus HLD, ADASPOR™ Plus HLD RTU, ISASPOR™ HLD
- 2) Testing by ATS Labs of St. Paul, MN (protocol number MT01042903.COR). A ≥ 4.0 Log reduction of Human coronavirus ATCC VR-740, strain 229E in the presence of 5% soil on hard, non-porous surfaces using a disinfectant dilution of 1%. 229E HCV is a different coronavirus strain than SARS-CoV -2.
- 3) Testing by Microbiotest, Inc of Sterling, VA (protocol number 304-115). A ≥ 4.0 Log reduction of Human Immunodeficiency Virus type 1, Strain HTLV-III_{la}. Done in the presence of 5% soil on hard, non-porous surfaces using a disinfectant dilution of 1%.
- 4) W. Bond. Decreasing order of resistance of microorganisms to germicidal chemicals. Regulatory Framework for Disinfectants and Sterilants. 4th ed. Philadelphia, PA, 1991.
- 5) Testing by Microbiotest, Inc of Sterling, VA (protocol number 304-114). A ≥ 4.0 Log reduction of Poliovirus type 2, ATCC VR-1002, strain Lansing, in the presence of 5% soil on hard, non-porous surfaces using a disinfectant dilution of 1%
- 6) Product specifications, indications, contraindications, warnings, precautions and instructions for use can be found in the product labeling supplied with each product.